“…Many of these studies investigated the particular role of metabolites in inflammatory bowel diseases by using primarily NMR studies (Lin et al, 2011). Non-targeted metabolomics approaches in gut microbial sample matrices and liver, analysing changes occurring in metabolic diseases like obesity, are rarely given, but many studies addressed obesity-related metabolome characterization (Dumas et al, 2006;Williams et al, 2006;Fearnside et al, 2008;Li et al, 2008Li et al, , 2010aShearer et al, 2008;Newgard et al, 2009;Waldram et al, 2009;Kim et al, 2009Kim et al, , 2010Kim et al, , 2011Calvani et al, 2010;Xie et al, 2010Xie et al, , 2012Zhao et al, 2010;Oberbach et al, 2011;Duggan et al, 2011a,b;Jung et al, 2012;Hanhineva et al, 2013;Schäfer et al, 2014;Seyfried et al, 2013;Won et al, 2013;Xu et al, 2013;Daniel et al, 2014;Eisinger et al, 2014). Comparing with other studies, our study provides a greater insight into different metabolite classes that were involved in obesity-related changes by reflecting both bacterial and host metabolism.…”